Drug Profile


Alternative Names: ACEA 1021

Latest Information Update: 23 Dec 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Purdue Pharma
  • Class Quinoxalines; Small molecules
  • Mechanism of Action Glutamate receptor antagonists; Glycine NMDA-associated antagonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Craniocerebral trauma; Neurological disorders; Pain; Stroke

Most Recent Events

  • 23 Dec 2002 Discontinued - Phase-I for Neurological disorders in USA (IV)
  • 23 Dec 2002 Discontinued - Preclinical for Pain in USA (unspecified route)
  • 22 Mar 2001 A study has been added to the Pain pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top